KC
MLTX icon

Kryger Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

Kryger Capital’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-100,913
Closed -$998K – 248
2021
Q4 		$998K Buy
+100,913
New +$1M 0.06% 207

Other funds holding MLTX

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Kryger Capital's MLTX Position: Q1 2022 in Review

Kryger Capital sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2022, closing a stake of 100,913 shares — an estimated $998K sold.

Kryger Capital first reported a position in MLTX in Q4 2021 and held it in 1 quarter. The position peaked at $998K in Q4 2021. 27 funds tracked by Wall St. Rank hold MLTX as of Q1 2022.

  • Kryger Capital reported no remaining MoonLake Immunotherapeutics position as of Q1 2022 after selling out during the quarter.
  • Kryger Capital sold 100,913 MoonLake Immunotherapeutics shares in Q1 2022, an estimated $998K.
  • Kryger Capital first reported a position in MoonLake Immunotherapeutics in Q4 2021 and held it in 1 quarter.
  • Kryger Capital's MoonLake Immunotherapeutics position peaked at $998K in Q4 2021.
  • 27 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2022.

Based on Kryger Capital's 13F filing for Q1 2022, filed 12 May 2022.